Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports
Published on 09/06/2025 at 19:14

Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
516.20 DKK | -0.58% |
|
+5.27% | -17.30% |
06-13 | Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial | RE |
06-13 | Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing… | ![]() |
Published on 09/06/2025 at 19:14
Mr. Lars Fruergaard Jørgensen is a Vice President at European Federation of Pharmaceutical Industries & Assns, a Vice Chairman-Supervisory Board at Carlsberg A/S, a Member-Supervisory Board at Carlsberg Breweries A/S, a President & Chief Executive Officer at Novo Nordisk Ltd., a President & Chief Executive Officer at Novo Nordisk A/S and a Chairman at Harno Invest A/S. He is on the Board of Directors at Carlsberg A/S and Carlsberg Breweries A/S. Mr. Jørgensen was previously employed as a Member-Supervisory Board by Innate Pharma SA, a Vice President-Finance & Information Technology by Novo Nordisk Pharmaceutical SAS, and a Chairman by NNE Pharmaplan A/S. He also served on the board at ZymoGenetics, Inc. and NNIT A/S. He received his graduate degree from the University of Aarhus.
View full profileSelect your edition
All financial news and data tailored to specific country editions